2021 Online, In the cloud

III-01 Lisa Amann
Stepwise Covariate Modelling (SCM) versus Full Random Effects Modelling (FREM) for covariate modelling of correlated covariates exemplified with tigecycline and liver function markers
III-02 Kyle Baron
Development and validation of open-source pharmacometrics software using an iterative software development life cycle methodology: the pmtables R package for submission-ready table generation.
III-03 Julie Bertrand
Model-based approaches for bioequivalence studies with only one-time point measured drug concentration
III-04 Sabrina Boutaghou
On the influence of sampling schemes on the demonstration of bioequivalence
III-05 Núria Buil Bruna
Cheat sheet for pharmacometrics communication
III-06 Jung-woo CHAE
The effect of CYP2D6 phenotypes on the pharmacokinetics of propafenone: a systematic review and meta-analysis
III-07 Estelle Chasseloup
Individual Model Averaging to increase robustness in drug effect estimation
III-08 Chao Chen
Translational modelling and estimation of probability of molecule success on balance of pharmacology benefit and safety risk
III-09 David Cristinacce
PoPy: Population PKPD Analysis in Python
III-10 David Fairman
Towards Industrialisation of Probability of Pharmacological Success (PoPS)
III-11 Manu Francis
Subspace MCMC algorithm for Bayesian parameter estimation of hierarchical PK/PD models in Pumas
III-12 Leonid Gibiansky
Calibration of an IgG turnover model using data from administration of monoclonal antibodies targeting FcRn receptor
III-13 Jan Grzegorzewski
PK-DB: pharmacokinetics database for individualized and stratified computational modeling
III-14 Benjamin Guiastrennec
Improving the reproducibility of NONMEM-based pharmacometric analyses
III-15 Woo Jin Jung
Web based platform for clinical pharmacokinetic consultation service (CPCS) with Non-linear Mixed Effect Model
III-16 Lina Keutzer
Machine learning for covariate selection and prediction of pharmacokinetic data illustrated with rifampicin
III-17 Niklas Korsbo
Latexify.jl - An ecosystem for automatically transcribing Pumas and Julia objects into renderable equations.
III-18 Anne Kümmel
IQnca: An open-source R package for efficient and reproducible non-compartmental analysis in R
III-19 Silvia Maria Lavezzi
Evaluation of efficacy predictors and probability of pharmacological success for a novel compound to treat parasitic disease proposed for first-time-into-human
III-20 Félicien Le Louedec
Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayr
III-21 Christopher Rackauckas
Automated Machine Learning Acceleration of Pharmacometrics Models in Pumas with JuliaSim 
III-22 Quyen Tran
Overview of Korean Pharmacometrics Modeling Library and web-based pharmacometrics platform
III-23 Anastasia Tsyplakova
Development and validation of a population pharmacokinetic model for donepezil
III-24 Lisa van der Heijden
Extrapolation of Phase 0 microdosing trials: a naïve pooled data modelling approach.
III-25 Zhengguo Xu
Estimators and Confidence Intervals of f2 Using Bootstrap Methodology for the Comparison of Dissolution Profiles
III-26 Simone Zannoni
Investigating the identifiability of one-stage IVIVC population models for extended-release dosage forms
III-27 Elisa Borella
Vaborem pharmacokinetics and dose rationale in children
III-28 Elisa Borella
Oritavancin pharmacokinetics and dose rationale in children
III-29 Salvatore D'Agate
Model-based evaluation of beta-lactams in neonatal and paediatric sepsis
III-30 Eva Degraeuwe
Population pharmacokinetic modeling of lisinopril at steady-state in hypertensive pediatric patients with mild to moderate renal impairment
III-31 Esther Encinas
Simulation of systemic exposure after multiple ocular administration of bilastine ophthalmic solution for safety assessment in children
III-32 Aline Engbers
Lack of pharmacokinetic interaction between doxapram and caffeine for the treatment of preterm infants with apnea
III-33 Alan Faraj
Phase-3 dose selection of marzeptacog alfa (activated) in children enabled by model-informed drug development techniques
III-34 Kinga Fiebig
Prospective evaluation of a novel model-based dosing guideline for gentamicin in preterm and term neonates
III-35 Anthony Gebhart
A semi-physiologically based pharmacokinetics approach to predict hepatic and gut wall intrinsic clearances of midazolam in pediatric patients: preliminary results filling the gap between preterm neonates and infants above 1 year
III-36 Iztok Grabnar
Pharmacokinetic-pharmacodynamic model of fentanyl sedation in children with severe acute bronchiolitis
III-37 Ana-Marija Grisic
Population pharmacokinetic model of avelumab in a pediatrics population
III-38 Soumya Perinparajah
A Novel Mechanistic Mathematical Model for CD19+ B Cell Reconstitution after Paediatric Haematopoietic Stem Cell Transplantation
III-39 Maša Roganović
Population pharmacokinetic modelling of cyclosporine in paediatric kidney transplant patients using routine TDM data
III-40 Rajendra Singh
Determination of the individual pharmacokinetic exposure parameter uncertainty to support of pediatric exposure-response trial design
III-41 Rajendra Singh
Population pharmacokinetic analysis of deutetrabenazine (AUSTEDO) in children and adolescents with Tourette Syndrome
III-42 Erik Sjögren
Lumenfantrine Exposure in Malnourished Children: PBPK modeling applied for Predictions and Dose Adjustments
III-43 Tomás Sou
Caplacizumab Model-Based Dosing Recommendations In Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura
III-44 Aartje Maria van der Kuijl
Quantifying requirements for additional sedatives in critically-ill children using a repeated time to event analysis
III-45 Louvina van der Laan
Pharmacokinetics of para-aminosalicylic acid in children treated for multidrug-resistant tuberculosis.
III-46 Yunjiao Wu
Pre- and postnatal maturation are important for fentanyl exposure in preterm and term newborns: a pooled population pharmacokinetic study
III-47 Jurij Aguiar Zdovc
Model-based individualization of ustekinumab dosing in Crohn's disease
III-48 Orwa Albitar
A Pharmacokinetic and Pharmacodynamic Model of Cyclosporine among Malaysian Renal Transplant Patients
III-49 Muhammad Waqar Ashraf
A population pharmacokinetic model to quantify the role of in-vivo CYP2D6 activity in codeine metabolism for model informed precision dosing in ambulatory surgical patients.
III-50 Rebecca Baillie
Reuse of a published model to support compassionate use of novel drug formulation for a rare disorder
III-51 Amina Bensalem
The influence of underlying disease on rituximab pharmacokinetics may be explained by target-mediated drug disposition
III-52 Rene Boosman
The pemetrexed exposure-neutropenia relationship, paving the way to a safe administration in patients with an impaired renal function
III-53 Divakar Budda
Prediction of CNS Target Engagement of Pain reliving Drugs in Health and Chronic Pain conditions
III-54 Laura Bukkems
Population pharmacokinetics of Haemate P describing the interaction between factor VIII and Von Willebrand Factor levels in perioperative patients with von Willebrand Disease
III-55 Vera Bukkems
A combined modelling approach to assess the efficacy and safety of doravirine in pregnant women
III-56 Elisa Calvier
TMDD model to extrapolate free target reduction from competitor data in healthy volunteers to another drug in patients in order to select active dose range for phase II trials
III-57 Fernando Carreño
Modelling of Dose-Response-Time Data Using a Population k-PD approach for Linerixibat, a Locally Acting Small Molecule with Minimal Systemic Absorption
III-58 Myriam Chartoire
Development of mechanistic models for analysis and interpretation of cough challenge test data
III-59 Perrine Courlet
Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control
III-60 Wilbert de Witte
Continuous Time Markov Modelling in Systemic Lupus Erythematosus
III-61 Tayebeh Esmaeili
Rivaroxaban Population Pharmacokinetics Modeling in Iranian Patients
III-62 Yu Fu
A novel hemodynamic systems model to quantify pharmacodynamic effects on heart rate and contractility
III-63 Frédéric Gaspar
A step towards Ticagrelor individualization based on pharmacokinetic approaches: which place for Physiologically-Based Modelling?
III-64 Mélanie Guhl
Model-based analysis of PK equivalence: assessing the impact of model misspecification
III-65 Khalid Iqbal
A PK-PD modelling and simulation-based evaluation of tedizolid dosing strategies for immunocompromised patients
III-67 Ranita Kirubakaran
Matters close to the heart: adaptation of a tacrolimus model to inform tacrolimus therapy using the PRIOR approach
III-68 Christine Juliane Kleist
Homoarginine population kinetics
III-69 Jane Knöchel
Markov model demonstrates the importance of fibrosis distribution on clinical trial design in NAFLD/NASH
III-70 Niklas Kroemer
Development and evaluation of D-optimal 2x2 checkerboard designs for identification of pharmacodynamic drug interactions
III-71 Julia Larsson
A second-generation challenge model of TNFa turnover with LPS provocations and drug intervention
III-72 Li Li
Model-Based Approach for assessing the Effect of Anti-Drug Antibodies on the PK of Therapeutic Proteins
III-73 Qiang Lu
Semi-mechanistic Population Pharmacokinetic/Pharmacodynamic (Pop PK/PD) Modeling of Dupilumab on Nasal Congestion (NC) Score in Patients with Chronic Rhinosinusitis with Nasal Polyposis
III-74 Bastien Martin
In silico clinical trial simulation shows amelioration of ischemia-reperfusion injury in ST-elevation myocardial infarction via inhibition of reactive oxygen species production
III-75 Saikumar Matcha
Population Pharmacokinetics of Unbound Phenytoin after Administration of IV Fosphenytoin And Oral Phenytoin in Pediatric Patients.
III-76 Nicola Melillo
Development and validation of a physiologically-based pharmacokinetic model of the imaging biomarker gadoxetate for prospective prediction of hepatic transporters drug-drug interactions
III-77 Yomna Nassar
Quantifying the dynamics of the modulatory effect of CYP3A perpetrators on hepatic CYP3A activity using a nonlinear mixed-effects model of microdosed midazolam and its metabolite 1-hydroxymidazolam
III-78 Karine Elena Rodriguez
Pharmacometric characterization of entero-hepatic circulation processes of orally administered formulations of amiodarone under complex binding kinetics
III-79 Benjamin Schneider
A Quantitative Systems Pharmacology Model for Bedside Optimization of ACE Inhibitor Dose Scheduling in Veterinary Cardiology
III-80 Daniel Seeler
Towards understanding vascular (dys)regulation by linking endothelial cell morphology and blood vessel geometry
III-81 Hwang Sejung
Effect of CYP2D6 genotype on pharmacokinetics and pharmacodynamics of carvedilol for the heart rate reduction in healthy subjects
III-82 manna semere gebreyesus
Population pharmacokinetics of esomeprazole in pregnant women with preterm preeclampsia
III-83 Monica Simeoni
A Model Based Meta-Analysis for Bridging Treatment Doses of Rheumatoid Arthritis with Axial Spondyloarthritis
III-84 Leonid Stolbov
A QSP approach to investigate the glucose-insulin dynamic following dapagliflozin treatment in patients with type 2 diabetes mellitus
III-85 David Ternant
In-depth description of target-mediated pharmacokinetics of infliximab in inflammatory bowel disease patients
III-86 Wisse van Os
Targeted temperature management reduces CYP2C19 metabolism: a population pharmacokinetic study using pantoprazole
III-87 Zhigang Wang
Pharmacokinetic-Pharmacodynamic Model-Based Exploration of Alternative Ustekinumab Dosage Regimens for Patients with Crohn’s Disease
III-88 Liang Yang
A quantitative pharmacology model for CB1 receptor mediated by Gi Gs protein competition
III-89 Miren Zamacona
Population pharmacokinetic and exposure-response models for dapirolizumab pegol in patients with systemic lupus erythematosus
III-90 Chiara Zecchin
mPBPK and PD modelling and simulation to predict drug and pharmacodynamic effect at site of action and guide the design of a phase 2A/B study